Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in adolescents with homozygous familial hypercholesterolemia
NCT04659863Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Oct 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Part 1 - Inclisiran with Part 1 - Placebo (2 arms). Primary endpoint: Low-Density Lipoprotein Cholesterol at Day 330. Started Feb 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT04659863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659863.